{"drugs":["Renvela","Sevelamer Carbonate"],"mono":{"0":{"id":"928903-s-0","title":"Generic Names","mono":"Sevelamer Carbonate"},"1":{"id":"928903-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928903-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> serum phosphorus greater than 5.5 and less than 7.5 mg\/dL, initial, 800 mg ORALLY 3 times a day with meals<\/li><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> serum phosphorus greater than or equal to 7.5 mg\/dL, initial, 1600 mg ORALLY 3 times a day with meals<\/li><li><b>End stage renal disease - Hemodialysis - Hyperphosphatemia:<\/b> dose titration, increase or decrease by 800 mg per meal at 2 week intervals, with a target serum phosphorus goal of 3.5 mg\/dL to 5.5 mg\/dL<\/li><\/ul>"},"1":{"id":"928903-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy of sevelamer carbonate in pediatric patients have not been established "},"3":{"id":"928903-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>End stage renal disease - Hemodialysis - Hyperphosphatemia<br\/>"}}},"3":{"id":"928903-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928903-s-3-9","title":"Contraindications","mono":"bowel obstruction <br\/>"},{"id":"928903-s-3-10","title":"Precautions","mono":"<ul><li>swallowing disorders; dysphagia and esophageal tablet retention have been reported, some severe requiring intervention and\/or hospitalization; consider change to suspension formulation<\/li><li>bowel obstruction and intestinal perforation have been reported<\/li><li>report known or suspected adverse events to the United States Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928903-s-3-11","title":"Pregnancy Category","mono":"Sevelamer: C (FDA)<br\/>"},{"id":"928903-s-3-12","title":"Breast Feeding","mono":"Sevelamer: Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"928903-s-4","title":"Drug Interactions","sub":{"2":{"id":"928903-s-4-15","title":"Moderate","mono":"<ul><li>Ciprofloxacin (established)<\/li><li>Levothyroxine (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><\/ul>"}}},"5":{"id":"928903-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Abdominal pain, Constipation, Diarrhea, Flatulence, Indigestion, Nausea, Vomiting<br\/><b>Serious<\/b><br\/><b>Gastrointestinal:<\/b>Bowel obstruction, Perforation of intestine, Peritonitis<br\/>"},"6":{"id":"928903-s-6","title":"Drug Name Info","sub":{"0":{"id":"928903-s-6-17","title":"US Trade Names","mono":"Renvela<br\/>"},"2":{"id":"928903-s-6-19","title":"Class","mono":"<ul><li>Bile Acid Sequestrant<\/li><li>Phosphate Binder<\/li><\/ul>"},"3":{"id":"928903-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928903-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"928903-s-7","title":"Mechanism Of Action","mono":"Sevelamer carbonate, a non-absorbed calcium-free and metal-free crosslink polymer, binds with phosphate molecules through ionic and hydrogen bonding and reduces phosphate absorption in the dietary tract, thereby lowering the serum phosphate concentration.<br\/>"},"8":{"id":"928903-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928903-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability: oral: not systemically absorbed<\/li><li>Effects of food: should be given with meals but not with enteral nutrition<\/li><\/ul>"},"3":{"id":"928903-s-8-26","title":"Excretion","mono":"Fecal: 100% <br\/>"}}},"9":{"id":"928903-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>medications whose bioavailability, safety, and efficacy may be significantly affected by concurrent administration with sevelamer carbonate should be given at least 1 hr before or 3 hr after sevelamer carbonate<\/li><li>take 3 times a day with meals<\/li><li>(powder for suspension) empty contents of 0.8 g powder packet in 30 mL of water and 2.4 g packet in 60 mL of water and mix vigorously (does not dissolve); multiple packets may be mixed together with appropriate amount of water; entire mixture should be consumed within 30 mins of preparation or resuspend mixture right before drinking (powder for suspension)<\/li><\/ul>"},"10":{"id":"928903-s-10","title":"Monitoring","mono":"<ul><li>serum phosphorus levels<\/li><li>vitamin D, vitamin E, vitamin K (clotting factors) and folic acid levels<\/li><li>serum bicarbonate, chloride, and calcium levels<\/li><\/ul>"},"11":{"id":"928903-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 800 MG<br\/><\/li><li><b>Renvela<\/b><br\/><ul><li>Oral Powder for Suspension: 0.8 GM\/Packet, 2.4 GM\/Packet<\/li><li>Oral Tablet: 800 MG<\/li><\/ul><\/li><\/ul>"},"13":{"id":"928903-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause abdominal pain, constipation, diarrhea, dyspepsia, nausea or vomiting.<\/li><li>Instruct patient to report new onset or worsening constipation to prevent severe complications.<\/li><li>Patient should take with meals and adhere to prescribed diet.<\/li><\/ul>"}}}